Caribou Biosciences, Inc. CRBU
0.36 USD -0.02 (-4.81%)
At closeNov 13, 2026, 4:00 PM EST
0.36 0.00 -0.50%
After hours · Nov 13, 4:00 PM ET
0.36 Day range 0.3802
0.36 52-week range 2.49
- YTD
- -77.24%
- 1 year
- -81.81%
News
zacks.com Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Caribou Biosciences (CRBU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
zacks.com Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
globenewswire.com Caribou Biosciences Reports Third Quarter 2026 Financial Results BERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026.
zacks.com Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Caribou Biosciences (CRBU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations…
benzinga.com Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
benzinga.com This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose…
benzinga.com This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…
benzinga.com Nasdaq Falls Over 100 Points; US Crude Inventories Decline U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
benzinga.com This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday Analysts downgraded PJT, OPCH, CRBU, ABEV , cutting price targets for PJT, CRBU.
benzinga.com Dow Tumbles 350 Points; Constellation Brands Earnings Top Views U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
benzinga.com RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1 RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall as 30-Year Treasury Yield Hits 2002 High; Iran Mocks US Economy — STZ, PENG, LEVI in Focus (UPDATED) U.S. stock futures were lower on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Tuesday's higher close.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
benzinga.com Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1 Leerink Partners analyst Daina Graybosch downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Market Perform and lowers the price target from $4 to $1.
benzinga.com Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech, mining and other stocks declined premarket.
benzinga.com Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket Penguin Solutions jumped 7.7% after beating Q4 revenue/EPS estimates and issuing above-consensus FY27 EPS guidance.
benzinga.com Levi Strauss, Constellation Brands and 3 Stocks to Watch Heading Into Wednesday Stocks in focus: Levi Strauss and Applied Digital report earnings; Caribou halts programs; Constellation raises guidance; Richardson reports.
benzinga.com Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why Caribou Biosciences shares fall 35% after hours as the company weighs strategic alternatives and cuts two drug programs.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…
benzinga.com Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder…
globenewswire.com Caribou Biosciences to Evaluate Strategic Alternatives -- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
zacks.com Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall…
defenseworld.net BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
zacks.com Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
defenseworld.net Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75 Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com…
benzinga.com B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5 B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
zacks.com Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.- benzinga.com Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of…
globenewswire.com Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update -- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to…
zacks.com Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
globenewswire.com Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel…- benzinga.com Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MM -- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months ---- Case…
globenewswire.com Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient…
globenewswire.com Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting -- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case…
marketbeat.com Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate…
seekingalpha.com Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
globenewswire.com Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,…
benzinga.com Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026…- benzinga.com HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11 HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from $9 to $11.
benzinga.com Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 39.53 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday.
- benzinga.com Gold Down Over 1%; ClearOne Shares Spike Higher U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also…
- benzinga.com Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.